These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26725672)

  • 1. [The Pharmacist as Gatekeeper of Prescription Drug Abuse: Return to "Community Scientists"].
    Shimane T
    Yakugaku Zasshi; 2016; 136(1):79-87. PubMed ID: 26725672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacist as gatekeeper: combating medication abuse and dependence].
    Shimane T
    Yakugaku Zasshi; 2013; 133(6):617-30. PubMed ID: 23728090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical behavior of Japanese community pharmacists for preventing prescription drug overdose.
    Shimane T; Matsumoto T; Wada K
    Psychiatry Clin Neurosci; 2015 Apr; 69(4):220-7. PubMed ID: 25112197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An opioid dispensing and misuse prevention algorithm for community pharmacy practice.
    Rickles NM; Huang AL; Gunther MB; Chan WJ
    Res Social Adm Pharm; 2019 Aug; 15(8):959-965. PubMed ID: 29525483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacist utilization of prescription opioid misuse interventions: Acceptability among pharmacists and patients.
    Riley TB; Alemagno S
    Res Social Adm Pharm; 2019 Aug; 15(8):986-991. PubMed ID: 30665825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Factors Necessary for Gatekeeper of Overdose.
    Nagashima K; Hiruma K; Nakamura E; Watanabe M; Sekine Y
    Biol Pharm Bull; 2024 Jan; 47(1):112-119. PubMed ID: 37967973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges faced with opioid prescriptions in the community setting - Australian pharmacists' perspectives.
    Makdessi CJ; Day C; Chaar BB
    Res Social Adm Pharm; 2019 Aug; 15(8):966-973. PubMed ID: 30819418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of overlapping prescriptions of psychotropic drugs by community pharmacists.
    Shimane T; Matsumoto T; Wada K
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2012 Oct; 47(5):202-10. PubMed ID: 23393998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
    Bailey AM; Wermeling DP
    Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moving opioid misuse prevention upstream: A pilot study of community pharmacists screening for opioid misuse risk.
    Strand MA; Eukel H; Burck S
    Res Social Adm Pharm; 2019 Aug; 15(8):1032-1036. PubMed ID: 30031696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription drug abuse communication: A qualitative analysis of prescriber and pharmacist perceptions and behaviors.
    Hagemeier NE; Tudiver F; Brewster S; Hagy EJ; Hagaman A; Pack RP
    Res Social Adm Pharm; 2016; 12(6):937-948. PubMed ID: 26806859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using the theory of planned behavior to investigate community pharmacists' beliefs regarding engaging patients about prescription drug misuse.
    Fleming ML; Bapat SS; Varisco TJ
    Res Social Adm Pharm; 2019 Aug; 15(8):992-999. PubMed ID: 30442574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current situation of suicide in Japan, and what pharmacists contribute to suicide prevention].
    Matsumoto T
    Yakugaku Zasshi; 2013; 133(6):599-615. PubMed ID: 23728089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical counseling: Between evidence-based medicine and profits.
    Egorova SN; Akhmetova T
    Int J Risk Saf Med; 2015; 27 Suppl 1():S87-8. PubMed ID: 26639727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol.
    Nielsen S; Kowalski M; Wood P; Larney S; Bruno R; Shanahan M; Lenton S; Dietze P; Green T; Murnion B; Ritter A
    Res Social Adm Pharm; 2019 Aug; 15(8):1047-1055. PubMed ID: 30396825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacist-led interventions for the management of medication misuse and abuse: A systematic review.
    Baum L; Badejo G; Chaboyer K; Leong C
    J Am Pharm Assoc (2003); 2017; 57(3):297-298. PubMed ID: 28268072
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulating gabapentin as a drug of abuse: A survey study of Kentucky community pharmacists.
    Blackmer J; Lindahl E; Strahl A; Schadler A; Freeman PR
    J Am Pharm Assoc (2003); 2019; 59(3):379-382. PubMed ID: 30786971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
    Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
    Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of risks associated with the prescribing and dispensing of oral anticancer medicines in Ireland.
    Hammond L; Marsden E; O'Hanlon N; King F; Henman MC; Keane C
    Int J Clin Pharm; 2012 Dec; 34(6):893-901. PubMed ID: 22961608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic and safety benefits of pharmaceutical interventions by community and hospital pharmacists in Japan.
    Tasaka Y; Yasunaga D; Tanaka M; Tanaka A; Asakawa T; Horio I; Miyauchi Y; Araki H
    Int J Clin Pharm; 2016 Apr; 38(2):321-9. PubMed ID: 26744362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.